Dynamic Technology Lab Private Ltd acquired a new stake in Cambrex Corporation (NYSE:CBM) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 3,987 shares of the biotechnology company’s stock, valued at approximately $238,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in CBM. BlackRock Inc. lifted its stake in Cambrex Corporation by 0.5% in the 2nd quarter. BlackRock Inc. now owns 4,023,607 shares of the biotechnology company’s stock valued at $240,409,000 after purchasing an additional 20,652 shares during the last quarter. Vanguard Group Inc. lifted its stake in Cambrex Corporation by 4.6% in the 1st quarter. Vanguard Group Inc. now owns 3,138,934 shares of the biotechnology company’s stock valued at $172,799,000 after purchasing an additional 139,010 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Cambrex Corporation by 0.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,330,254 shares of the biotechnology company’s stock valued at $79,483,000 after purchasing an additional 11,762 shares during the last quarter. Congress Asset Management Co. MA lifted its stake in Cambrex Corporation by 8.7% in the 2nd quarter. Congress Asset Management Co. MA now owns 1,297,023 shares of the biotechnology company’s stock valued at $77,497,000 after purchasing an additional 103,900 shares during the last quarter. Finally, FMR LLC lifted its stake in Cambrex Corporation by 19.1% in the 2nd quarter. FMR LLC now owns 1,070,645 shares of the biotechnology company’s stock valued at $63,971,000 after purchasing an additional 171,559 shares during the last quarter.

In other Cambrex Corporation news, CEO Steven M. Klosk sold 12,000 shares of the company’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $51.53, for a total value of $618,360.00. Following the completion of the sale, the chief executive officer now directly owns 95,328 shares of the company’s stock, valued at approximately $4,912,251.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Steven M. Klosk sold 4,000 shares of the company’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $54.96, for a total transaction of $219,840.00. Following the completion of the sale, the chief executive officer now directly owns 87,328 shares of the company’s stock, valued at $4,799,546.88. The disclosure for this sale can be found here. Corporate insiders own 2.48% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://theolympiareport.com/2017/11/01/dynamic-technology-lab-private-ltd-acquires-shares-of-3987-cambrex-corporation-cbm.html.

CBM has been the subject of several recent analyst reports. Zacks Investment Research downgraded shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, July 4th. BidaskClub downgraded shares of Cambrex Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, August 24th. ValuEngine downgraded shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Finally, Craig Hallum reiterated a “buy” rating and issued a $60.00 target price (down from $70.00) on shares of Cambrex Corporation in a research note on Tuesday. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $62.33.

Shares of Cambrex Corporation (NYSE:CBM) opened at 43.25 on Wednesday. Cambrex Corporation has a 12 month low of $38.30 and a 12 month high of $62.95. The firm’s 50-day moving average is $52.72 and its 200 day moving average is $55.05. The firm has a market capitalization of $1.42 billion, a P/E ratio of 15.76 and a beta of 2.28.

Cambrex Corporation (NYSE:CBM) last issued its quarterly earnings data on Friday, August 4th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.76. Cambrex Corporation had a net margin of 17.70% and a return on equity of 24.25%. The business had revenue of $134.55 million during the quarter, compared to the consensus estimate of $136.82 million. During the same period in the prior year, the firm posted $0.68 EPS. The firm’s quarterly revenue was up 13.4% compared to the same quarter last year. On average, equities research analysts anticipate that Cambrex Corporation will post $3.08 EPS for the current year.

Cambrex Corporation Company Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Corporation (NYSE:CBM).

Institutional Ownership by Quarter for Cambrex Corporation (NYSE:CBM)

Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.